9OSW | pdb_00009osw

Tetrameric POLQ Helicase-like Domain Bound to Cmpd 19, a Small-Molecule ATPase Inhibitor and Drug Candidate Analog


Experimental Data Snapshot

  • Method: ELECTRON MICROSCOPY
  • Resolution: 2.67 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

The Discovery of RP-2119: A Potent, Selective, and Orally Bioavailable Pol theta ATPase Inhibitor.

Mochirian, P.Papp, R.Mathieu, M.C.Ferraro, G.B.Dietrich, E.Liu, B.Bendahan, D.Perryman, A.L.Surprenant, S.Fournier, S.Barzili, B.L.Bonneau-Fortin, A.Yin, S.Y.Leclaire, M.E.Patel, C.Poirier, H.Save, S.Mathieu, Y.Morin, N.Godbout, C.Burston, H.E.Zahn, K.E.Attia, M.A.Pinter, T.Barabe, F.Parikh, P.Jagani, C.Kang, G.Scapin, G.Mamane, Y.Sfeir, A.Mader, P.Sicheri, F.Zimmermann, M.Roulston, A.Morris, S.J.Black, W.C.Gallant, M.

(2025) J Med Chem 68: 19726-19745

  • DOI: https://doi.org/10.1021/acs.jmedchem.5c02103
  • Primary Citation of Related Structures:  
    9OSW, 9OSY

  • PubMed Abstract: 

    DNA polymerase theta (Polθ) plays a critical role in repairing DNA double-strand breaks through microhomology-mediated end joining (MMEJ) and has emerged as a key synthetic lethal drug target in cancers with homologous recombination (HR) deficiencies. Its inhibition has shown a strong potential to synergize with PARP inhibitors, particularly in tumors with deleterious BRCA1 or BRCA2 mutations. Here, we describe the discovery and preclinical development of RP-2119, a selective, potent, and bioavailable Polθ ATPase inhibitor. Starting from a high-throughput ATPase screen combined with literature insights, key vectors for enhancing potency were identified by structural studies using single-particle cryo-electron microscopy (cryo-EM) that revealed the inhibitor binding site. Further optimization of potency and ADME properties led to the identification of RP-2119 with robust in vitro cellular activity in a wide range of HR-deficient cancer cell lines. In HR-deficient cell line- and patient-derived mouse xenografts, RP-2119 demonstrated strong synergy with the PARP inhibitor, olaparib, without exacerbating its hematological toxicity.


  • Organizational Affiliation
    • Repare Therapeutics, 7171 Frederick-Banting, Building 2, H4S 1Z9 Montréal, Québec, Canada.

Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
DNA polymerase theta
A, B, C, D
904Homo sapiensMutation(s): 0 
Gene Names: POLQPOLH
EC: 3.6.4.12 (PDB Primary Data), 2.7.7.7 (PDB Primary Data), 2.7.7.49 (PDB Primary Data)
UniProt & NIH Common Fund Data Resources
Find proteins for O75417 (Homo sapiens)
Explore O75417 
Go to UniProtKB:  O75417
PHAROS:  O75417
GTEx:  ENSG00000051341 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupO75417
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: ELECTRON MICROSCOPY
  • Resolution: 2.67 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 
EM Software:
TaskSoftware PackageVersion
MODEL REFINEMENTPHENIX1.19.2_4158

Structure Validation

View Full Validation Report



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Not funded--

Revision History  (Full details and data files)

  • Version 1.0: 2025-09-17
    Type: Initial release
  • Version 1.1: 2025-10-01
    Changes: Data collection, Database references